Phase 1 Study of TG01 and Erlotinib in Non-small Cell Lung Cancer (NCSLC) Patients
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, phase 1, dose escalation study. The purpose is to
determine the highest dose of TG01 that can be safely given to patients with Non-Small Cell
Lung Cancer in combination with erlotinib.